Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
S*BIO completes enrollment in SB1518 JAK2 inhibitor Phase 2 clinical trials for myelofibrosis

S*BIO completes enrollment in SB1518 JAK2 inhibitor Phase 2 clinical trials for myelofibrosis

Four-year follow-up results from SPRYCEL Phase 3 study in CML-CP presented at ASCO

Four-year follow-up results from SPRYCEL Phase 3 study in CML-CP presented at ASCO

New technique to prevent tumours developing in connection with stem cell transplantations

New technique to prevent tumours developing in connection with stem cell transplantations

MicroStockProfit.com: ARIA reports net loss of $23.4M for three months ended March 31, 2010

MicroStockProfit.com: ARIA reports net loss of $23.4M for three months ended March 31, 2010

Clarient granted U.K. patent for TLE3 biomarker

Clarient granted U.K. patent for TLE3 biomarker

Hana Biosciences reports complete data from Marqibo Phase 2 RALLY trial for relapsed/refractory adult ALL

Hana Biosciences reports complete data from Marqibo Phase 2 RALLY trial for relapsed/refractory adult ALL

Polaris' ADI-PEG 20 novel anticancer drug inhibits growth of metastatic melanoma cells: Study

Polaris' ADI-PEG 20 novel anticancer drug inhibits growth of metastatic melanoma cells: Study

Research findings open door to development of new therapies for lymphomas, leukemias

Research findings open door to development of new therapies for lymphomas, leukemias

Researchers discover RAF oncogene that may drive aggressive forms of prostate cancer

Researchers discover RAF oncogene that may drive aggressive forms of prostate cancer

GTx presents quality of life results from Ostarine Phase IIb study in cancer cachexia patients at ASCO 2010

GTx presents quality of life results from Ostarine Phase IIb study in cancer cachexia patients at ASCO 2010

Synta presents positive clinical results from STA-9090 Hsp90 inhibitor trials in solid tumors at ASCO 2010

Synta presents positive clinical results from STA-9090 Hsp90 inhibitor trials in solid tumors at ASCO 2010

ARIAD presents updated positive data on AP24534 pan-BCR-ABL inhibitor for CML at 46th ASCO

ARIAD presents updated positive data on AP24534 pan-BCR-ABL inhibitor for CML at 46th ASCO

Researchers present data from Phase II study of lenalidomide in patients with untreated CLL at ASCO

Researchers present data from Phase II study of lenalidomide in patients with untreated CLL at ASCO

Cyclacel reports positive interim data from sapacitabine Phase 2 study for myelodysplastic syndromes

Cyclacel reports positive interim data from sapacitabine Phase 2 study for myelodysplastic syndromes

Hana Biosciences signs Investment Agreement with Warburg Pincus and Deerfield Management

Hana Biosciences signs Investment Agreement with Warburg Pincus and Deerfield Management

CytRx granted U.S. Patent for bafetinib

CytRx granted U.S. Patent for bafetinib

BioSante's GVAX CML Vaccine granted FDA Orphan Drug designation

BioSante's GVAX CML Vaccine granted FDA Orphan Drug designation

Phase I study results of Pharmacyclics' PCI-32765 Btk inhibitor for B cell NHL presented at ASCO

Phase I study results of Pharmacyclics' PCI-32765 Btk inhibitor for B cell NHL presented at ASCO

MD Anderson-led Phase III clinical study determines Sprycel superior to Gleevec as front-line therapy

MD Anderson-led Phase III clinical study determines Sprycel superior to Gleevec as front-line therapy

Array BioPharma presents positive Phase 1 clinical data of ARRY-520 KSP inhibitor for multiple myeloma

Array BioPharma presents positive Phase 1 clinical data of ARRY-520 KSP inhibitor for multiple myeloma

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.